| Name | Title | Contact Details |
|---|
Antibe Therapeutics develops safer medications for chronic pain and inflammation. Today, physicians and consumers rely principally on non-steroidal anti-inflammatory drugs (NSAIDs), a $12 billion category of medications that includes brands like Advil, Aleve, Motrin, Celebrex, Voltaren and Aspirin. While effective, NSAIDs can cause gastrointestinal damage and bleeding. To address this serious medical need, Antibe has patented a technology for linking NSAID molecules to hydrogen sulfide molecules. More than a decade of academic and applied research has demonstrated that hydrogen sulfide, when appropriately delivered, can protect the gastrointestinal tract and enhance the anti-inflammatory effectiveness of today’s NSAIDs. Beginning with its IPO in mid-2013, Antibe has raised more than $10 million and initiated human clinical trials of its first drug, aimed at mild to moderate pain.
BioConvergence is a Bloomington, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Orion Genomics is a Saint Louis, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
AltruBio is developing first-in-class immune-modulators targeting diseases of #immunology and #inflammation. Its world-class global team brings a breadth of expertise in immunology and drug development that will help advance their biologic treatments to patients.
At Quantum-Si we have a created a very unique environment where bright, highly committed individuals are given the freedom, ownership, and resources to solve tough problems and be the first to do new science. We are fully-funded by successful founders so employees can focus on creating, building, learning, and getting to market products that will change the world.